Contrafect investor relations
WebSep 6, 2024 · YONKERS, N.Y., Sept. 06, 2024 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has completed enrollment in the … WebDec 13, 2024 · YONKERS, N.Y., Dec. 13, 2024 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the …
Contrafect investor relations
Did you know?
WebDec 18, 2024 · Investor Relations Contacts: Michael Messinger ContraFect Corporation Tel: 914-207-2300 Email: [email protected] Lauren Stival Stern Investor Relations Tel: 212-362-1200 Email:... WebMar 31, 2024 · 8-K: CONTRAFECT Corp. Published: March 31, 2024 at 5:37 p.m. ET. The MarketWatch News Department was not involved in the creation of this content. (EDGAR Online via COMTEX) -- CONTRAFECT Corp ...
WebMar 31, 2024 · As of December 31, 2024, ContraFect had cash, cash equivalents and marketable securities of $13.7 million. About ContraFect: ContraFect is a biotechnology … WebContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital …
WebAug 15, 2024 · YONKERS, N.Y., Aug. 15, 2024 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents... WebMar 31, 2024 · The MarketWatch News Department was not involved in the creation of this content. YONKERS, Mar 31, 2024 (GLOBE NEWSWIRE via COMTEX) -- YONKERS, N.Y., March 31, 2024 (GLOBE NEWSWIRE) -- ContraFect ...
WebApr 6, 2024 · ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new …
WebMay 26, 2024 · Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Relations Contact. Michael Messinger ContraFect Corporation seat protection for car seatshttp://ir.contrafect.com/ seat protection from car seatsWebMar 31, 2024 · CONTRAFECT CORPORATION Statements of Operations (in thousands, except share and per-share data) In this release, management has presented its financial position as of December 31, 2024 and its operating results for the three months and years ended December 31, 2024 and 2024 in accordance with U.S. Generally Accepted … puck schoolWebInvestors & Media. Overview; News / Events; Presentations; Company Information; Financial Information; Analyst Coverage; Stock Data; SEC Filings; Corporate Governance; Careers; ... Contrafect Corporation. We are focused on developing first-in-class biologic therapies for life-threatening, drug-resistant infectious diseases. ... seat protector for dogWebApr 6, 2024 · ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting. 2024-04-06 08:30 ET - News Release. Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa. New Data Elucidating the Mechanism of Action of CF-370. seat protector running and retrieving toolWebMar 17, 2024 · Investor Relations Contact. Michael Messinger ContraFect Corporation Tel: 914-207-2300 Email: [email protected]. Carlo Tanzi, Ph.D. Kendall … seat protector for rear car seatWebMar 31, 2024 · YONKERS, N.Y., March 31, 2024 (GLOBE NEWSWIRE) -- ContraFect Corporation(Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic … seat protector potty training